Biogen Says European Commission Revokes Marketing Authorizations For Generic Versions Of TECFIDERA
(RTTNews) - Biotechnology company Biogen, Inc. (BIIB) announced Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's product TECFIDERA (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva.
In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA.
Biogen said this decision confirms to the laws governing data exclusivity and marketing protection which are essential to protecting innovation.
TECFIDERA is entitled to marketing protection until February 3, 2025, and is the only dimethyl fumarate treatment for multiple sclerosis that may be lawfully placed on the market for sale in the EU until that date.
Biogen has initiated legal action to defend its market protection rights and has sufficient supply of TECFIDERA to supply the entire European market.
Biogen Q2 Results Top Estimates; Boosts FY24 Outlook
Biogen Says European Commission Grants TOFIDENCE Biosimilar Approval For Multiple Indications
Biogen To Buy Human Immunology Biosciences In Deal Valued At Up To $1.8 Bln
Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook
Biogen Q2 Results Top Estimates; Backs FY23 Outlook
Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook
Biogen Q4 Results Top Estimates
